Mr. Chairman, thank you, and thanks to Ms. Fraser for being here.
I'm totally convinced that everybody who sits around this table has the best interests of our aboriginal peoples at heart, and that's why we've chosen to serve on this committee.
I certainly agree with Mr. Lemay that we don't want this report and its good recommendations to simply sit here gathering dust and come back to it five years from now to find that nothing has been done.
As I look through the number of issues you identified here, on 15 of which you felt there was unsatisfactory progress, there's obviously a failure to comply with some of the recommendations. My question would be, is it just a failure, is it a reluctance, or is it even possibly a resistance to comply on the part of management?
As I look at a number of the issues here in the appendix, chapter 5, item 15.71 referring to Health Canada, telling us that this measure in terms of assessing prescription drug misuse is not feasible and couldn't be implemented, I don't know all of the nuances behind that answer, but it strikes me as a strange comment in a recommendation that was made.
In addition, on page 4, item 12.121, it states that the small amount of additional information gained from changing its systems would not be worth the investment. And you could go on down that page; there are three others identified on that page.
You indicate that special attention by management is one of the key factors in addressing these issues. My question is, how can we as a committee ensure that management continues to give the kind of sustained attention to these issues? Secondly, if you have time to answer this question, you've identified 15 shortcomings--again, in terms of identifying and addressing all 15, we may get to those--but if we had to prioritize three of them, are there three that would rise to the top? You may not be prepared to answer that today, but it would be helpful for me if, in the future, we could have those prioritized.
Thank you.